{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T19:51:16Z","timestamp":1775505076481,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.clon.2026.104067","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:20:58Z","timestamp":1769732458000},"page":"104067","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical Features Associated With Outcomes in Lung Cancer Patients Treated With Denosumab"],"prefix":"10.1016","volume":"52","author":[{"given":"B.-W.","family":"Shiau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.-H.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.-F.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.-C.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3320-1680","authenticated-orcid":false,"given":"C.-Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.clon.2026.104067_bib1","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","article-title":"The global burden of lung cancer: current status and future trends","volume":"20","author":"Leiter","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.clon.2026.104067_bib2","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/annonc\/mdv001","article-title":"European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?","volume":"26","author":"Malvezzi","year":"2015","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.clon.2026.104067_bib3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/JTO.0000000000000051","article-title":"Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer\u2013CSP-HOR 13","volume":"9","author":"Katakami","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.clon.2026.104067_bib4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.lungcan.2015.04.007","article-title":"The incidence and clinical impact of bone metastases in non-small cell lung cancer","volume":"89","author":"Kuchuk","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clon.2026.104067_bib5","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2018.05.006","article-title":"Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer","volume":"121","author":"Kuijpers","year":"2018","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.clon.2026.104067_bib6","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2026.104067_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.588862","article-title":"High prevalence and early occurrence of skeletal complications in EGFR-mutated NSCLC patients with bone metastases","volume":"10","author":"Lagana","year":"2020","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.clon.2026.104067_bib8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jtho.2015.10.001","article-title":"Effect of bisphosphonates, denosumab, and radioisotopes on bone pain and quality of life in patients with non-small cell lung cancer and bone metastases: a systematic review","volume":"11","author":"Hendriks","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1016\/j.clon.2026.104067_bib9","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2026.104067_bib10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ctrv.2017.10.010","article-title":"The anti-tumor effect of RANKL inhibition in malignant solid tumors: a systematic review","volume":"62","author":"de Groot","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.clon.2026.104067_bib11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/JTO.0000000000000070","article-title":"RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases","volume":"9","author":"Miller","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1016\/j.clon.2026.104067_bib12","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study","volume":"7","author":"Scagliotti","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1016\/j.clon.2026.104067_bib13","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1097\/CORR.0000000000001749","article-title":"Which bone-modifying agent is associated with better outcomes in patients with skeletal metastases from lung cancer? A systematic review and network meta-analysis","volume":"479","author":"Bozzo","year":"2021","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.clon.2026.104067_bib14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2021.09.002","article-title":"Combined, patient-level analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC \u2013 the ETOP\/EORTC SPLENDOUR and AMGEN-249 trials","volume":"161","author":"Peters","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clon.2026.104067_bib15","article-title":"Efficacy and safety of concomitant immunotherapy and denosumab in patients with advanced non-small cell lung cancer carrying bone metastases: a retrospective chart review","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"issue":"14","key":"10.1016\/j.clon.2026.104067_bib16","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.3390\/cancers14143470","article-title":"Overall survival improvement in patients with epidermal growth factor receptor-mutated non-small cell lung cancer and bone metastasis treated with denosumab","volume":"14","author":"Ko","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clon.2026.104067_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.697298","article-title":"Immune checkpoint inhibitors with or without bone-targeted therapy in NSCLC patients with bone metastases and prognostic significance of neutrophil-to-lymphocyte ratio","volume":"12","author":"Bongiovanni","year":"2021","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.clon.2026.104067_bib18","doi-asserted-by":"crossref","first-page":"4668","DOI":"10.21037\/jtd-21-150","article-title":"Does denosumab offer survival benefits? Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors","volume":"13","author":"Cao","year":"2021","journal-title":"J Thorac Dis"},{"issue":"6","key":"10.1016\/j.clon.2026.104067_bib19","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00432-017-2350-5","article-title":"Impact of denosumab use on the survival of untreated non-squamous non-small cell lung cancer patients with bone metastases","volume":"143","author":"Udagawa","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"10.1016\/j.clon.2026.104067_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"key":"10.1016\/j.clon.2026.104067_bib21","unstructured":"TriNetX. TriNetX publication guidelines. Available at: https:\/\/trinetx.com\/real-world-resources\/publications\/trinetx-publication-guidelines\/. Accessed 2025."},{"issue":"7","key":"10.1016\/j.clon.2026.104067_bib22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.6879","article-title":"Association of survival and immune-related biomarkers with immunotherapy in patients with non-small cell lung cancer: a meta-analysis and individual patient-level analysis","volume":"2","author":"Yu","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"14","key":"10.1016\/j.clon.2026.104067_bib23","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2217\/imt-2021-0135","article-title":"Chemotherapy or chemo-immunotherapy as first-line treatment for extensive-stage small-cell lung cancer: a meta-analysis","volume":"13","author":"Chen","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.clon.2026.104067_bib24","first-page":"e64","volume":"7","author":"Alderman","year":"2025"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526000385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526000385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T19:02:16Z","timestamp":1775502136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655526000385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":24,"alternative-id":["S0936655526000385"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2026.104067","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Features Associated With Outcomes in Lung Cancer Patients Treated With Denosumab","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2026.104067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}],"article-number":"104067"}}